Bile Reflux Gastropathy: Prevalence & Risk Factors After Therapeutic

Status Completed

Clinical Trial Summary

Bile reflux gastropathy is caused by the backward flow of duodenal fluid into the stomach. A retrospective cohort study was performed to declare if the therapeutic biliary interventions cause bile reflux gastropathy, and to estimate its prevalence and risk factors, and to evaluate the gastric mucosa endoscopic and histopathologic changes.

Clinical Trial Description

Bile reflux gastropathy is a pathological condition in the form of the backward flow of duodenal fluid that consists of bile, pancreatic juices, and secretions of the intestinal mucosa into the stomach and esophagus, causing mucosal lesions. Bile acids, in combination with gastric acid, have been shown to cause bile reflux gastropathy symptoms (heartburn, regurgitation, epigastric pain, etc.). Bile reflux gastropathy frequently occurs after gastric surgeries that that damages the pyloric sphincter, and after biliary surgeries and procedures as cholecystectomy, endoscopic sphincterotomy (EST), endoscopic stenting, or choledochoduodenostomy that cause the sphincter of Oddi malfunction.[4] Bile gastropathy is a normal physiological event in a prolonged fasting period (primary bile reflux gastropathy).In non-responsive individuals to PPI medication, the total prevalence of biliary reflux was 68.7%. These people have acid and bile reflux at the same time and have never had biliary surgery. Endoscopic retrograde cholangiopancreatography (ERCP) became an increasingly popular modality for both the diagnosis and the treatment of biliary tract disorders. It represents one of the most demanding and technically challenging procedures in gastrointestinal endoscopy, which must be performed effectively and safely by operators with substantial training and experience to maximize success and safety. Cholecystectomy is a surgical operation of gallbladder removal. It can be performed either laparoscopically, using a video camera, or via an open surgical technique. Pain and complications caused by gallstones are the most common reasons for cholecystectomy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05131802
Study type	Observational
Source	Zagazig University
Contact
Status	Completed
Phase
Start date	January 1, 2018
Completion date	December 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06094062` - Smartphone App-assisted PPI	N/A
Completed	`NCT03941288` - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia	Phase 2
Completed	`NCT04429802` - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity	N/A
Not yet recruiting	`NCT06369753` - Visible Abdominal Distension	N/A
Withdrawn	`NCT02863822` - Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.	N/A
Recruiting	`NCT00978159` - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia	Phase 4
Completed	`NCT00723502` - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients	Phase 2
Completed	`NCT00217347` - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy	N/A
Completed	`NCT00148603` - Montelukast in the Treatment of Duodenal Eosinophilia	N/A
Terminated	`NCT00220844` - Tricyclic Antidepressants (TCAs) on Gastric Emptying	N/A
Completed	`NCT00164996` - Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia	Phase 3
Completed	`NCT00232037` - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia	Phase 3
Completed	`NCT00232102` - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia	Phase 3
Completed	`NCT00110968` - Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia	Phase 3
Recruiting	`NCT05718960` - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia	N/A
Completed	`NCT05750641` - The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
Terminated	`NCT04247100` - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders	N/A
Completed	`NCT03252743` - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.	N/A
Completed	`NCT04697641` - Helicobacter Pylori Eradication in Functional Dyspepsia	N/A
Recruiting	`NCT04918329` - Functional Digestive Disorders Observatory

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms